KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros Therapeutics (KROS) is focusing on its lead neuromuscular program, rinvatercept (KER-065), for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) in 2026. The drug aims to modulate transforming growth factor-beta family signaling to promote muscle growth and repair. Keros plans a Phase II study for DMD in Q3 2026, with initial data in H1 2027, and will discuss Phase II design for ALS with regulators in H2 2026.
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates
Keros Therapeutics, Inc. (KROS) reported a Q1 loss, missing revenue estimates. The company's financial performance highlights challenges in meeting market expectations for the quarter.
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Keros Therapeutics (KROS:NASDAQ) announced that the initiation of its Phase 2 rinvatercept study for Duchenne muscular dystrophy (DMD) will be delayed from Q2 2026 to Q3 2026 due to procedural regulatory hurdles. Wedbush Securities analyst Yun Zhong reiterated a Neutral rating with a US$16.00 price target, highlighting the delay is primarily operational and regulatory, not specific to Keros or rinvatercept. The company expects to present initial data from the DMD study in 1H 2027 and continues to advance its elritercept program with Takeda in myelofibrosis and myelodysplastic syndrome.
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16
Wedbush has reiterated its Hold rating on Keros Therapeutics (KROS.US) and maintained its target price at $16. This report indicates a continued neutral stance on the company's stock by the analyst firm.
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan
A director at Keros Therapeutics, Jean Jacques Bienaime, purchased 1,000 shares of common stock in an open-market transaction on May 15, 2026, at a weighted average price of $10.58 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following this purchase, his direct ownership in Keros Therapeutics (KROS) now totals 9,450 shares, though such pre-planned transactions are typically seen as routine rather than strong indicators of company prospects.
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates
Keros Therapeutics, Inc. (KROS) reported a wider-than-expected loss for the first quarter, posting a loss of $1.39 per share compared to analysts' estimates of $1.15 per share. The company also significantly missed revenue expectations, recording $849,000 against a forecast of $1.15 million. This financial performance has led to a 1.25% drop in stock value as of Thursday morning.
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial has reiterated its Buy rating on Keros Therapeutics (KROS.US). This indicates a continued positive outlook from the firm regarding Keros Therapeutics' stock performance and potential.
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS)
Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of 1,360,419 shares of Keros Therapeutics (NASDAQ: KROS). This stake represents 6.90% of the shares outstanding as of March 31, 2026. The Schedule 13G filing indicates shared voting and dispositive power over these shares, classifying Nantahala as an investment adviser and Harkey and Mack as control persons.
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Keros Therapeutics (KROS) reported a wider-than-expected first-quarter 2026 loss of $1.21 per share and a significant 99.8% year-over-year revenue plunge to $0.4 million, missing analyst estimates. The company's top line was impacted by the absence of license revenues compared to the prior year, with existing revenues primarily from transition services related to its Takeda agreement. Keros is advancing its pipeline, including a phase II study for rinvatercept in DMD and planned phase III studies for elritercept by partner Takeda.
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
Keros Therapeutics (KROS) reported a Q1 loss of $1.21 per share, missing the Zacks Consensus Estimate of a $0.92 loss, and significantly underperformed its earnings from a year ago. The company also missed revenue estimates, posting $0.37 million compared to an expected higher figure. The stock has seen a 41.1% decline year-to-date and currently holds a Zacks Rank #3 (Hold), indicating that shares are expected to perform in line with the market.
Keros Therapeutics 1Q 2026: Revenue $367K, EPS ($1.21) — 10-Q Summary
Keros Therapeutics reported its first-quarter 2026 financial results, with revenue significantly declining to $367K from $211.25M in the prior year, leading to a net loss of $23.71M or ($1.21) diluted EPS. This decline was primarily due to reduced license and milestone income following a partner transaction in 2025. The company also highlighted pipeline advancements for Rinvatercept and the transition of Elritercept development to Takeda.
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a significant decrease from a net income of $148.5 million in Q1 2025, primarily due to deferred revenue recognition from a Takeda license agreement and reduced R&D expenses. The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, which is expected to fund operations into the first half of 2028. Keros also highlighted Takeda's plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a swing from a $148.5 million net income in Q1 2025, primarily due to past Takeda license revenue and reduced R&D expenses. The company announced that its partner, Takeda, plans to advance elritercept into a Phase 3 clinical trial for anemia in myelofibrosis, expanding its potential indication beyond myelodysplastic syndromes. Keros projects its current cash and cash equivalents of $281.5 million will fund operations into the first half of 2028.
Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a significant swing from a net income of $148.5 million in Q1 2025, primarily due to the absence of substantial license revenue from Takeda recognized in the prior year. Revenue plummeted to $0.4 million from $211.2 million, though R&D expenses also decreased as Takeda assumed costs for elritercept. Keros expects its current cash and cash equivalents of $281.5 million to fund operations into the first half of 2028, with Takeda planning a Phase 3 trial for elritercept.
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Keros Therapeutics reported a net loss of $23.7 million in Q1 2026, a significant decrease from a net income of $148.5 million in Q1 2025, primarily due to revenue recognized from a Takeda license agreement in the prior year and reduced R&D expenses. The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, which is expected to fund operations into the first half of 2028. Keros also announced that its partner Takeda plans to advance elritercept into a Phase 3 clinical trial for treating anemia in myelofibrosis.
Keros Therapeutics Inc KROS
This page provides an overview of Keros Therapeutics Inc (KROS) stock, showing its current price, market capitalization, and P/E TTM. It includes sections for financial data, discussions, and analysis, and allows users to comment on the stock. The article displays real-time market data with a 15-minute delay and references risk warnings regarding investment products.
(KROS) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting a strong near-term sentiment with neutral mid and long-term outlooks. It details institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The analysis emphasizes a significant 112.7:1 risk-reward setup targeting a 29.2% gain.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts
Nine analysts have given Keros Therapeutics (NASDAQ:KROS) an average rating of "Hold," with a 12-month price target of $21.3333. The company's stock recently traded up 3.3% and has a market cap of $227.39 million. Keros Therapeutics missed analysts' consensus estimates for its last quarterly earnings, reporting ($0.86) EPS against an expected ($0.49).
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc
The sarcopenia market is projected to reach USD 5,626 million by 2034, growing at a CAGR of 10.6% from USD 2,276 million in 2025. Key companies like TNF Pharmaceuticals, Lipocine, and Biophytis are developing novel therapies, with several candidates in various stages of clinical development. The report highlights increasing prevalence and awareness of sarcopenia, alongside advancements in pipeline products, as major drivers for market growth, particularly in the US which held the largest market share in 2025.
Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday
Keros Therapeutics (KROS) is scheduled to release its Q1 2026 earnings before market open on Tuesday, May 5th, with analysts expecting a loss of ($1.02) per share and $1.688 million in revenue. The company previously missed estimates in Q4 2025, reporting ($0.86) EPS against a consensus of ($0.49) and revenue of $0.39 million, an 87.2% year-over-year decline. Keros currently holds a "Hold" rating from analysts with a consensus target price of $21.33, and its shares are trading near $11 with a market cap of approximately $218 million.
[ARS] Keros Therapeutics, Inc. SEC Filing
This article announces an ARS SEC filing by Keros Therapeutics, Inc. (KROS) on April 22, 2026. The filing has a low impact and neutral sentiment, and the document is available as a PDF. The article also provides KROS stock overview, rankings, latest news, and other SEC filings.
Keros Therapeutics (NASDAQ: KROS) focuses on rinvatercept and completes $375M capital return
Keros Therapeutics is holding its 2026 annual meeting on June 3, 2026, where stockholders will vote on director elections, auditor ratification, and executive compensation. The company has strategically shifted its focus to rinvatercept for Duchenne muscular dystrophy and other neuromuscular diseases, discontinuing internal development of cibotercept. Keros also completed a $375 million capital return program to stockholders through share repurchases.
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Keros Therapeutics (KROS) is focusing on rinvatercept development in 2026, with three key catalysts expected to influence investor sentiment. These include the planned Phase II initiation of rinvatercept in Duchenne muscular dystrophy (DMD) in Q2 2026, regulatory discussions for rinvatercept in ALS in H2 2026, and progress in Takeda's Phase III RENEW study for elritercept, which will trigger milestone payments and royalties for Keros. The company's financial stability and execution on these milestones will be crucial given the competition in the DMD treatment landscape and the volatility of its revenue stream.
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
Keros Therapeutics' (KROS) financial profile was significantly reshaped in 2025 by a licensing deal with Takeda, which led to a substantial increase in revenue and a reduction in R&D expenses. While this deal provides Keros with a cash runway into the first half of 2028, reducing near-term financing pressure, the dependence on unpredictable milestone payments rather than product sales introduces volatility. The company also reduced its share count through significant capital return actions and is valued based on its book value given the absence of commercial product sales.
KROS Rinvatercept: What to Know Before DMD Phase II Starts
Keros Therapeutics is focusing its pipeline on rinvatercept, a protein therapeutic for neuromuscular disorders like Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS). The company plans to initiate a Phase II study for DMD in Q2 2026, driven by an orphan drug designation and promising Phase I data showing muscle, fat, and bone benefits. While the strategy concentrates risk on rinvatercept, it aims to deliver a novel treatment approach against the backdrop of existing DMD therapies and their associated trade-offs.
Bienaime buys Keros Therapeutics (KROS) shares worth $11,700 By Investing.com
Keros Therapeutics director Jean Jacques Bienaime recently purchased 1,000 shares of the company's common stock for $11,700. This transaction was executed under a pre-arranged trading plan, and comes as the stock is down 43% year-to-date, though InvestingPro analysis suggests it may be undervalued. Keros Therapeutics also recently appointed Charles Newton to its Board of Directors to strengthen its leadership with financial expertise.
Bienaime buys Keros Therapeutics (KROS) shares worth $11,700
Director Jean Jacques Bienaime of Keros Therapeutics (KROS) recently purchased 1,000 shares worth $11,700 at prices between $11.56 and $11.80. This transaction was part of a pre-arranged trading plan, and the stock is considered undervalued by analysts, with price targets up to $30 despite a 43% year-to-date decline. Keros Therapeutics also appointed Charles Newton to its Board of Directors, aiming to strengthen its leadership with financial expertise.
Insider Buying: Jean Bienaime Acquires Additional Shares of Keros Therapeutics Inc (KROS)
Jean Bienaime, a Director at Keros Therapeutics Inc (KROS), recently purchased 1,000 shares, increasing his total holdings to 8,450 shares. This transaction is part of a trend where Bienaime has acquired 3,000 shares over the past year without any sales. The company's stock was trading at $11.70 per share, with a market cap of $230.097 million and a P/E ratio significantly lower than the industry median.
Bienaime buys Keros Therapeutics (KROS) shares worth $11,700
Bienaime, a director at Keros Therapeutics (NASDAQ:KROS), purchased 1,000 shares of the company's common stock for $11,700 on April 15, 2026. This transaction occurred via a pre-arranged Rule 10b5-1 trading plan, increasing his direct holdings to 8,450 shares. The purchase comes as Keros Therapeutics' stock is down 43% year-to-date, though analysis suggests it may be undervalued, and the company recently appointed Charles Newton to its Board of Directors.
Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock
Keros Therapeutics (NASDAQ:KROS) Director Jean Jacques Bienaime recently purchased 1,000 shares of the company's stock for $11,700.00, increasing his total holdings to 8,450 shares. This transaction, executed under a Rule 10b5-1 plan, occurred as the company reported a significant miss on quarterly earnings and revenue expectations. Analysts currently have a consensus "Hold" rating on Keros Therapeutics with a price target of $21.33.
[Form 4] Keros Therapeutics, Inc. Insider Trading Activity
Keros Therapeutics director Jean Jacques Bienaimé purchased 1,000 shares of the company's common stock at a weighted average price of $11.70 per share on April 15, 2026. This open-market purchase, made under a Rule 10b5-1 trading plan, increased his direct holdings to 8,450 shares. The trade was executed through multiple transactions with prices ranging from $11.56 to $11.80.
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March
Keros Therapeutics (NASDAQ:KROS) experienced a significant 24.9% decline in short interest during March, with total short interest falling to 1,494,814 shares, representing 9.5% of the company's shares. This translates to a short-interest ratio of 2.6 days based on average trading volume. The company recently missed quarterly earnings expectations, reporting an EPS of -$0.86 against an expected -$0.49 and revenue of $0.39M versus $3.66M expected, marking an 87.2% year-over-year revenue decrease.
Understanding the Setup: (KROS) and Scalable Risk
This article provides an analysis of Keros Therapeutics Inc. (NASDAQ: KROS), highlighting strong sentiment across all horizons but also indicating an elevated downside risk with a breakdown underway. It details various institutional trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis for near-term, mid-term, and long-term horizons. The analysis is based on AI-generated signals and quantitative research.
Wedbush Maintains Keros Therapeutics (KROS) Neutral Recommendation
This article states that Wedbush has reiterated its Neutral rating for Keros Therapeutics (KROS). It indicates that the previous price target was $54.00.
KROS SEC Filings - Keros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Keros Therapeutics (KROS) SEC filings, including 10-K, 10-Q, and 8-K forms, crucial for investors monitoring the clinical-stage biopharmaceutical company. It details corporate developments, financial results, and insider trading activities, with AI-powered tools summarizing key information. The filings cover topics like clinical trial data for lead candidates KER-065 and elritercept, capital allocation, and governance changes, serving as a primary source for understanding Keros's strategy and financial health.
BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics
BlackRock, Inc. has filed a Schedule 13G, reporting a 10.1% passive stake in Keros Therapeutics (KROS), owning 1,990,842 shares as of March 31, 2026. The filing indicates BlackRock's business units beneficially own these shares, with 1,960,306 shares carrying sole voting power. This disclosure is for investment purposes and does not signal intent to control or influence the company.
Keros Therapeutics (KROS) CEO exercises options for 55,000 shares
Jasbir Seehra, CEO of Keros Therapeutics (KROS), exercised employee stock options to acquire 55,000 shares of common stock at $0.30 per share on April 2, 2026. Following this transaction, his direct ownership increased to 440,708 shares of common stock. The options were immediately exercisable and had an expiration date of March 25, 2028.
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS
JPMorgan Chase & Co. significantly increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 260.8% in the third quarter, acquiring an additional 124,287 shares and now owning 171,941 shares valued at $2.72 million. This increase comes despite Keros Therapeutics missing its Q3 earnings and revenue expectations, reporting an EPS of ($0.86) against a consensus of ($0.49) and revenue of $0.39 million versus an expected $3.66 million. The biopharmaceutical company has a consensus "Hold" rating from analysts with a price target of $21.86, while the stock currently trades near $12.
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in Keros Therapeutics (NASDAQ: KROS) by 1,420.6% in the fourth quarter, acquiring an additional 92,212 shares, bringing its total to 98,703 shares valued at approximately $2.01 million. This increase occurred despite Keros Therapeutics reporting a weaker-than-expected quarter on March 4, with an EPS of ($0.86) against a consensus of ($0.49) and an 87.2% year-over-year revenue decline. The stock currently trades around $12, holding a consensus "Hold" rating from analysts with an average price target of $21.86.
The Technical Signals Behind (KROS) That Institutions Follow
This article analyzes the technical signals for Keros Therapeutics Inc. (NASDAQ: KROS) for institutional tracking. It highlights near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with warning of elevated downside risk due to a lack of long-term support signals. The article also provides AI-generated trading strategies with specific entry, target, and stop-loss levels for different risk profiles.
KROS Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for KROS, highlighting past quarterly results and future forecasts. It details revenue and EPS figures for recent quarters, including specific dates and surprise percentages. The article also covers analyst estimates for 2026/Q1, stock price correlation with forecast revisions, and historical stock price reactions around earnings reports to help investors with trading strategies.
[144] Keros Therapeutics, Inc. SEC Filing
This SEC filing (Form 144) for Keros Therapeutics, Inc. (KROS) reports a proposed sale of 45,057 shares of common stock with an aggregate market value of $497,429.28. The shares were acquired on April 13, 2020, through an IPO. The filing indicates a neutral impact and sentiment.
Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer
Keros Therapeutics announced that its Chief Legal Officer, Esther Cho, has been granted 80,000 employee stock options. These options have an exercise price of $15.52 per share and will expire on February 23, 2036. The vesting schedule begins on February 24, 2027, with the remaining options vesting quarterly, contingent on her continued employment.
Vanguard disaggregates holdings; reports 0 KROS shares (KROS)
The Vanguard Group has filed an amended Schedule 13G/A for Keros Therapeutics Inc. (KROS), reporting 0 shares beneficially owned, representing 0% of Keros common stock. This change follows an internal realignment on January 12, 2026, where certain subsidiaries will now report their holdings separately, in accordance with SEC Release No. 34-39538. The filing indicates that Vanguard no longer holds direct beneficial ownership over these securities.
KROS SEC Filings - Keros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to SEC filings for Keros Therapeutics (KROS), including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent filings detailing ownership changes, executive stock options, tender offers for share repurchase, and quarterly financial results, emphasizing the company's focus on TGF-ß pathway therapeutics. The platform also offers AI-powered summaries of these documents.
Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index
Keros Therapeutics, Inc. (NasdaqGM:KROS) has been removed from the S&P Biotechnology Select Industry Index. The company is a clinical-stage biopharmaceutical firm focusing on developing therapies for disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-B) family of proteins. Recent news includes collaborations for Lou Gehrig's disease treatment trials, additional clinical data, and earnings reports.
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones
This article analyzes Keros Therapeutics Inc. (KROS), highlighting divergent sentiment across trading horizons and suggesting choppy conditions. It provides AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategies with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, showing support and resistance levels for near-term, mid-term, and long-term periods.
KROS SEC Filings - Keros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Keros Therapeutics, Inc. (KROS) SEC filings, including 10-K, 10-Q, and 8-K forms, offering investors detailed regulatory disclosures on clinical programs, financial conditions, and corporate events. It highlights recent filings detailing insider ownership, material events, quarterly earnings, and significant trading activity by investment firms like ADAR1 Capital Management. The platform also offers AI-powered tools to summarize complex filings for easier understanding.
KROS stock: What to know about Rinvatercept in DMD
The article discusses KROS stock and provides information about Rinvatercept, a treatment related to Duchenne Muscular Dystrophy (DMD).
KROS stock: What to know about Rinvatercept in DMD
The article discusses Keros Therapeutics (KROS) and its drug Rinvatercept, which is being studied for its potential to treat Duchenne muscular dystrophy (DMD). Rinvatercept is designed to increase lean muscle mass by targeting ligands in the TGF-beta superfamily. The company is currently evaluating the drug in early-stage clinical trials.
